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·  ofthe EC-Treaty) :  I 
EXPLANATORY MEMORANDUM 
A.  Principles 
1.  In  September 1997  the  Commission  submitted  the  proposal  for  a  European 
Parliament and Council Directive on the approximation of provisions laid down by law, 
regulation  or  administrative  action  relating  to  the  implementation  of good  clinical 
practice  in  the  conduct  of  clinical  trials  on  medicinal  products  for  human  use 
[COM(97)369; 97/0197 (COD)] for adoption by the co-decision procedure laid down in 
Article 189b of  the Treaty establishing the European Community.  · 
The Economic and  Social  Committee was consulted for  its  opinion and,  at  its 
plenary  session  on  28 January 1998,  adopted  a  series  of amendments,  on  which  the 
Commission  has  given  its  opinion.  On  17 November 1998  the  European  Parliament 
adopted a series of amendments on first reading.  Qn this occasion the Commission gave 
its position on each amendment and indicated which it was going to include and which it 
could not accept. 
In the light of  the foregoing, the Commission has drafted this amended proposal. 
2.  The Commission has made two types of  amendment. 
First, additions have been made to numerous points in the original proposal which 
seemed too elliptic or could have been open to diverging interpretations when the time 
came for national legislation to implement them.  This explains the importance of the 
rewording of  the original text.  However, these are only clarifications or practical details 
and make no difference to the substance of the rules, which have just been reworded or 
presented in different form. 
Second, in response to the Economic and Social Committee's opinion and the first 
reading by the European Parliament, it was felt that new provisions should be added to 
bring the proposal closer into line with the  Community legislation already in force  on 
medicinal products and  ensure more efficient implementation of the Directive.  These 
new provisions are not only compatible with the subsidiarity principle but should ensure 
stronger application thereof. 
B.  Explanation of  the principal amendments 
1.  Informed consent 
To  guarantee  stronger  protection  of clinical  trial  subjects  and  in response  to 
European Parliament amendments 6, 8 and 10, new provisions on informed consent have 
been  added.  First,  a  practical  definition  has  been  added  in  Article 2  followed,  in 
Article 3(2), by procedures for giving or revoking such consent, particularly in the case of 
minors or of  incapacitated adults. 
The amended text also lays down clearer conditions for clinical trial subjects who 
so  wish  to  have  access  to  an  independent  contact able  to  supply  them  with  further 
information.  To this  end,  Article 3(4)  clearly places responsibility for  organising the 
corresponding arrangements  on the  sponsor,  ending,  at the  same  time,  the  legitimate 
concerns about confidentiality. 
1a 2.  Ethics committee 
- To  underline  that  this  committee  is  the  ethical  authority and  that  it  is  essential  to 
obtain  its  favourable  opinion  first  and  to  avoid  confusion  about  the  unique  function 
which  it alone  is  empowered  to  exercise,  Article 4(4)  defines  the  role  of the  ethics 
committee in greater detail compared with the  role of the  competent authorities in  the 
Member States  which  exercise the  exclusive  prerogatives of the  public  authorities  on 
authorisation (Article 7(4)),  control  (Article 10(1)  and  (2)  and  Article 13),  information 
(Article 9) and, where appropriate, penalties (Article 1  0(3)). 
- The amended proposal gives the ethics committee a stronger role, no  longer limited 
almost exclusively to the phase preceding commencement of  the clinical trial, as was the 
case -in  the  original  ·proposal.  In  this  connection,  in  line · with  Parliament's 
amendments 21, 22 and 27, the content of the information to be submitted to the ethics 
committee has been widened substantially to  cover the entire clinical trial, from before 
commencement to completion.  This includes: pharmacovigilance data, with the concepts 
of events and  reactions  now covered by  two  separate  Articles  (14  and  15);  measures 
taken by the competent authorities during the clinical trial in the event of shortcomings 
on the part ofthe sponsor or investigator (Article 10(1) and (2)); knowledge of  the result 
of inspections  to  verify compliance with good  clinical practice  during  conduct of the 
clinical trial (Article 13(2)). 
- The procedures for referring to the committee for its opinion have been clarified by 
creating a stronger link between Article 4(4) and (5) and Article 7(1) and (2), the effect of 
which is to draw a clear distinctio!l between the different phases before commencement 
of a  clinical  trial.  It has  also  been  made  clear  that  the  ethics  committee  must  be 
reconsulted if  the sponsor makes sul;>stantial amendments to the protocol being followed 
which  could  impair  subjects'  safety  and,  therefore,  call  into  question  the  original 
favourable  opinion  (new  Article 8(1)).  This  is  the  reason  for  splitting  the  original 
Article 7 and adding a new Article 8 covering activities well after the start of  the clinical 
trial. 
- Finally!  Article 5(2)  clearly  defines  the  role  and  relative  positions  of the  ethics 
committee or committees for the different sites involved in the same clinical trial on the 
one hand and the ethics committee chosen to  issue  the  single opinion on a particular 
clinical trial at Member State level on the other. 
3.  ;xcbanaes of  information 
Since around 60% of  the multi-centre clinical trials today involve several Member 
States, it is  imperative to  exchange information between the Member States involved, 
both on commencement of the clinical trials and on progress with them.  For example, 
. information on  the results of the clinical trials is  primordial for mutual recognition of 
national  marketing  authorisations  for  medicinal  products.  Strict  application  of the 
subsidiarity  principle  combined  with  geographical  centralisation  of these  data  in  a 
specialised base  with  all  the  requisite protection  would  greatly  facilitate  such  mutual 
recognition. 
To  this  end,  the  amended  proposal  reinforces  the  original  text  by  adding 
provisions on the practical arrangements for such centralisation at Community level (new 
Article 9(1)) and clearly defining the role played by the Commission in organising and 
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coordinating  such  exchanges  of  information  (Article 9(4))  vis-a.,·vis  the  competent 
authorities and the sponsor of  the clinical trial. 
4.  Compatibility with existing Communitv legislation 
It was found that the origimil Commission proposal was not fully compatible with 
the  principles  and  objectives  of  the  current  centralised  marketing  authorisation 
procedures for medicinal products, as set out in the Commission communication on the 
subject'. 
In this context, the European Agency for the Evaluation of Medicinal Products is 
responsible for evaluating all medicinal products derived from biotechnological processes 
(Part A of  the Annex to Council Regulation (EEC) No 2309/93).  It is therefore essential 
for  the  Agency  to  know  of the  existence  and  content  of the  clinical  trials  on  such 
products, as it will have to analyse the relevant clinical data when evaluating the products 
with  a  view to  granting  them  a  Community  marketing  authorisation.  Consequently, 
Article 7(3) of the amended proposal makes it mandatory to send the Agency a copy of 
the notification of commencement of a clinical trial  so  that  it  can assess  the  content 
thereof in preparation for subsequent evaluation of  the product should it fall under Part A 
of the Annex to Regulation (EEC) No 2309/93.  If the product falls under Part B of the 
same Annex, the sponsor has the option of  deciding whether or not to notify the Agency. 
5.  Procedure for commencement of  a clinical trial 
Based on Parliament's amendments 15  and  18,  the biggest change made to  the 
original proposal concerns the procedure for commencement of clinical trials.  The new 
procedure deliberately opts for simplification, which should equal speed and efficiency, 
by  putting  the  accent  on  the  "notification  procedure".  For the  sponsor  this  entails 
informing the competent authorities of  any plans to proceed with a clinical trial, by means 
of  a "notification".  The content and safeguards for monitoring this notification procedure 
are laid down in detail in Article 7(1) and (2). 
In  practice,  the  notification  is  equivalent  to  tacit  authorisation  which  the 
·competent authorities have full  powers to  revoke before it takes effect, exercising their 
power to raise grounds for non-acceptance as laid down in Article 7(2).  The notification 
procedure also draws a clear distinction between the prerogatives of  the ethics committee 
and the powers of the competent authorities in the Member States, as mentioned irt the 
first paragraph of Section B.2.  In any event, only the competent authorities may issue 
- written authorisation for a clinical trial, where such authorisation is mandatory. 
In the case of  clinical trials on medicinal products covered by Part A of  the Annex 
to Regulation (EEC) No 2309/93, the amended proposal specifies that this notification of 
the  clinical  trial  must  be  accompanied  by  a  written  authorisation  granted  by  the 
competent authorities of the Member States concerned within the time limits set in the 
amended proposal (Article 7(4)). 
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I  Original text 
Proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL 
DIRECTIVE 
on the approximation of  provisions laid down by 
law, regulation or administrative action relating to 
the implementation of  good clinical practice in the 
conduct of  clinical trials on medicinal products for 
human use 
Amended text 
Proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL 
DIRECTIVE ... /  .  ./EC 
on the approximation of  the laws, regulations and 
administrative provisions of  the Member States 
relating to the implementation of  good clinical 
practice in the conduct of  clinical trials on 
medicinal products for human use 
THE  EUROPEAN  PARLIAMENT  AND  THE  THE  EUROPEAN  PARLIAMENT  AND  THE 
COUNCIL OF THE EUROPEAN UNION,  COUNCIL OF THE EUROPEAN UNION, 
, Having regard to the Treaty establishing the 
European Community, and in particular Article 
1  OOa thereof, 
Having  regard  to  the  Treaty  establishing  the 
European  Community,  and  in  particular  Article' 
1  OOa thereof, 
Having  regard  to  the .  proposal  from  the  Having  regard  to  the  proposal  from  the 
Commission,  Commissions, 
Having regard to the opinion of  the Economic and 
Social Committee, 
Having regard to the opinion of  the Economic and 
Social Committee6, 
Acting in accordance with the procedure laid 
down in Article 189b ofthe Treaty, 
Acting in accordance with the procedure laid down 
in Article 189b of  the Treaty, 
Whereas  Council  Directive  65/65/EEC1  reqlJ,tres  (1) 
that  applications  for  authorisation  to  place  a 
medicinal  product  on  the  market  should  be 
accompanied  by  a  dossier  containing particulars 
arid documents relating to the results of tests and 
clinical trials carried out on the product; whereas 
Council  Directive  75/318/EEC2  lays  down 
I  OJ No L 22, 9.2.1965, p. 369/65. 
2  OJ No L 147, 9.6.1975, p.  I. 
3  OJNoL281,23.ll.l995,p.3l 
4  OJNoL l47,9.6.1975,p.l3. 
5  OJ No C 306, 8.10.1997, p. 9. 
6 OJ No C 95, 30.3.1998, p.  l. 
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(Unchanged) uniform  rules  on  the  compilation  of dossiers 
including their presentation; 
Whereas  the  accepted  basis  for  the  conduct  of 
clinical trials in humans is  founded in the current 
revision  of the  Declaration  of Helsinki  and  the 
Council of Europe Convention for the  protection 
of human rights  and dignity of the human being 
with  regard  to  the  application  of biology  and 
medicine; whereas the trial subject's protection is 
safeguarded  through  risk  assessment  based  on 
toxicological  experiments  prior  to  any  clinical 
trial, screening by ethics committees and Member 
States  authorities  and  the  protection of personal 
data; 
(2) Whereas the accepted basis for the  conduct of 
clinical  trials in humans  is  founded  in  the  current 
revision  of the  Declaration  of Helsinki  and  the 
Council of Europe Convention for the protection of 
human rights and dignity of the human being with 
regard to  the application of biology and medicine; 
whereas  the  clinical  trial  subject's  protection  is 
safeguarded through risk assessment based on the 
results  of toxicological  experiments  prior  to  any 
clinical  trial,  screening  by  ethics  committees  and 
Member States' competent authorities, and rules on 
the protection of  personal data; 
(3) Whereas it is incumbent on the Member States 
to  lay  down  rules  to  safeguard  protection  of 
individuals  who  are  incapable  of  giving  their 
consent,  such  as  minors  and  incapacitated  adults; 
whereas such persons are incapable of giving their 
free consent to take part in a clinical trial; whereas, 
therefore, such consent must be given in writing by 
their  parents  or  their  guardian  or  their  legal 
representative; 
Whereas, in order to achieve optimum protection  (  4) 
of  health,  the  resources  _allocated  to 
pharmaceutical research must not be  squandered 
(Unchanged) 
on obsolete or repetitive tests whether within the 
Community  or  in  third  countries;  whereas,  the 
harmonisation  of technical  requirements  for  the 
development  of  medicinal  products  should 
therefore be pursued through the appropriate. fora, 
including  the  International  Conference  on 
Harmonisation; 
7  OJ No L 214, 24.8.1993, p.l. 
8  OJNoL 193, 17.7.l99l,p.30. 
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(  5)  Whereas  for .  medicinal products falling  within 
the  scope  of Part  A  of .the  Annex  to  Council 
Regulation  (EEC)  No  2309/937,  which  include 
products intended for gene therapy or cell therapy, 
prior scientific evaluation by the European Agency 
for  the Evaluation of Medicinal Products, assisted 
by  the  Committee  for  Proprietary  Medicinal 
Products,  is  mandatory  before  the  Commission ------------------------------------ grants  marketing  authorisation;  whereas  in  the 
course  of  this  evaluation  the  Committee  may 
request full details of the results of the clinical trials 
on  which  the  application  for  marketing 
authorisation  is  based  and,  consequently,  on  the 
manner  in  which  these  trials  were  conducted  and 
the same Committee may go so far as to request the 
applicant  for  marketing  authorisation  to  conduct 
further clinical trials;  whereas, therefore, provision 
must be made to allow the abovementioned Agency 
to  have  full  information  on  the  conduct  of any 
clinical trial proposed for such medicinal products; 
Whereas, for multi-centre clinical trials conducted  (  6) 
in  more  than  one  Member  State,  with  many 
investigational  sites  involved,  a  delay  in  the 
commencement of the trial may be caused by the 
multiplicity  and  diversity  of  procedures  for 
obtaining opinions of ethics committees; whereas, 
(Unchanged) 
for such trials, a single opinion for each _]vfember 
State  concerned  reduces  delays  without 
jeopardising  the  well-being  of  the  people 
participating  in  the  trial  with  the  possibility  of 
_  rejecting  it ·in  specific  sites  if facilities  are  not 
appropriate; 
Whereas information both on the commencement 
and on the termination of a clinical trial should be 
available  to  the  Member  States  where  the  trial 
takes  place,  and  relevant  information  on clinical 
trials  should  be  exchanged  between  Member 
States; 
(7)  Whereas  information  on  the  content, 
commencement and  termination of a  clinical  trial 
should be available to the Member States where the 
trial  takes  place  and  all  the  other Member  States 
must  have  access  to  the  same  information  which 
will be indispensable for them at the time of  mutual 
recognition of the marketing authorisations for  the 
corresponding  medicinal  product  or  products; 
whereas,  therefore,  a  European  database  bringing 
together this confidential information should be set 
up; 
(8) Whereas clinical trials are a complex operation, 
generally  lasting  one  or  more  years,  usually 
involving  numerous  participants  and  several ·trial 
sites,  often  in  different  Member  States;  whereas 
Member  States'  current  practices  diverge 
considerably  on  the  rules  on commencement  and 
.conduct of the clinical trials and the requirements 
for  carrying  them  out  vary  widely;  whereas  this 
therefore  results  in  delays  and  complications 
detrimental to effective conduct of  such trials in the 
4 Community;  whereas  it  is  therefore  necessary  to 
harmonise these practices in order to simplify and 
shorten  them  by  establishing  a  clear,  transparent 
procedure  at:td  creating  conditions  conducive  to 
effective coordination of such clinical trials by the 
Community  authorities  concerned,  thereby 
favouring completion of  the internal market; 
Whereas  the  standards  of  good  manufacturing  (9) 
practice  should  be  applied  to  investigational 
medicinal products; whereas special provisions for 
the labelling of investigational medicinal products 
should be set out; · 
Whereas  verification  of  compliance  with  the  (10) 
standards of good clinical practice and the need to 
subject  data,  information . and  documents  to 
inspection in order to confirm that they have been 
properly  generated,  recorded  and  reported  .  is 
essential  in order to justify  the  involvement  of 
human  subjects  in  clinical  trials;  whereas  the 
person  participating  in  a  trial  should  be  made 
aware of and consent to the scrutiny of personal 
information  during  inspection  by  competeo.t 
authorities  and  properly  authorised  persons, 
provided that such personal information is treated 
as  strictly confidential and  is  not made publicly 
available; 
Whereas  this  Directive  is  without  prejudice  to  ( 11) 
Directive 95/46/EEC of the European Parliament 
and of the  Council  of 24  October  1995  on the 
protection  of  individuals  with  regard  to  _the 
processing  of  personal  data  and  on  the  free 
movement of  such data3; 
Whereas  it is also necessary to  make provisions  (12) 
for the monitoring of adverse reactions occurring 
in  clinical  trials  using  Community  surveillance 
(pharmacovigilance) procedures in order to ensure 
the  immediate  cessation  of any  clinical  trial  in 
which there is an unacceptable level of  risk; 
(Unchanged) 
(Unchanged) 
(Unchanged) 
(Unchanged) 
Whereas  the  conduct  of  clinical  trials  must  (13)  Whereas  the  conduct  of clinical  trials  must 
regularly  be  adapted  to  scientific  and  technical  regularly  be  adapted  to  scientific  and  technical 
progress in order to ensure optimum protection of  progress in order to ensure optimum protection of 
the trial subject; whereas it is therefore necessary  the trial subject; whereas it is therefore necessary to 
to  introduce  a  rapid  procedure  for  adapting  to  introduce  a  rapid  procedure  for  adapting  to 
k •  ... L'1ical  progress the requirements regarding the  technical  progress  the requirements  regarding  the 
conduct of  clinical trials, whilst ensuring close co- conduct of clinical trials, whilst ensuring close co-
5 operation  between  the  Commission  and  the  operation between the Commission and the Member 
Member  States  within  a  'Committee  for  the  States within a 'Standing Committee on Medicinal 
Adaptation to Technical Progress of  the Directives  Products for Human Use', 
on the Removal of Technical Barriers'" to-Trade in 
the Medicinal Products Sector', 
HAVE ADOPTED THIS DIRECTIVE:  HAVE ADOPTED THIS DIRECTIVE: 
1. 
2. 
CHAPTER I 
Scope and definitions 
Article 1 
This  Directive  deals  with  clinical  trials 
including  multi-centre  trials  on  human 
subjects  involving  medicinal  products  as 
defined  in  Article  1  of  Directive 
65/65/EEC but excludes non-interventional 
clinical trials. 
Good  clinical  practice  (GCP)  is  an 
international ethical and  scientific quality 
standard  for  designing,  conducting, 
recording and reporting trials that involve 
the  participation  of  human  subjects. 
Compliance  with  this  standard  provides 
public assurance that the rights, safety and 
well-being of trial  subjects are  protected, 
consistent  with  tfie  principles  that  have 
their origin in the Declaration of Helsinki 
(1964),  and  that the clinical trial data are 
credible. 
Scope 
Article 1 
1.  The  purpose  of this  Directive  is  to  lay  down 
provisions  relating ·to  the  implementation of good 
clinical  practice  in  the  conduct  of clinical  trials, 
including  multi-centre  trials,  on  human  subjects 
designed to develop medicinal products, as defined 
.in  Article  1 of Council Directive 65/65/EEC. This 
Directive  shall  not  apply  to  non-interventional 
clinical trials. 
2.  Good clinical practice is a set of internationally 
recognised  ethical  and  scientific  quality 
requirements  which  must  be  observed  for 
designing,  conducting,  recording  and  reporting 
clinical  trials  that  involve  the  participation  of 
human subjects. Compliance with this good practice 
provides assurance· that the rights, safety and well-
being of  trial subjects are protected, consistent with 
the  principles  set  out  in  the  amended  1964 
Declaration of Helsinki, and that the results of the 
clinical trials are credible. 
3.  The  principles  and  guidelines  of good  3.  (Unchanged) 
clinical  practice  shall  be  adopted  in  the 
form  of  a  directive  addressed  to  the 
Member  States,  in  accordance  with  the 
procedure  laid  down  in  Article  2c  of 
Council  Directive  75/318/EEC.  Detailed 
guidelines  in  line  with  those  principles 
shall be published by the Commission and 
revised  as  necessary  to  take  account  of 
technical and scientific progress. 
4.  All clinical trials, including bioavailability  4.  (Unchanged) 
and  bioequivalence  studies,  shall  be 
6 designed,  conducted  and  reported  in 
accordance  with  the  standard  of  good 
clinical practice. 
Article 2 
Definitions 
Article 2 
For the  purposes of this  Directive the  following  For  the  purposes  of this  Directive  the  following 
definitions shall apply:  definitions shall apply: 
Adverse Event: Any untoward medical occurrence 
in  a  patient  or  clinical  investigation  subject 
administered a medicinal product and which does 
not necessarily have a causal relationship with this 
treatment. 
Adverse  Reaction:  All  noxious  and  unintended 
responses to an investigational medicinal product 
related to any dose. 
Clinical  Trial:  Any  investigation  in  human 
subjects intended to discover or verify the clinical, 
pharmacological  and/or  other  pharmacodynamic 
effects of an investigational medicinal product(s), 
and/or  to  identify  any  adverse  reactions  to  an 
investigational  medicinal  product(s),  and/or  to 
study  absorption,  distribution,  metabolism,  and 
excretion of an investigational product(s) with the 
object of  ascertaining its safety and/or efficacy. 
This includes clinical trials done in either one site 
or. multiple sites; whether in one Member State or 
more than one Member State; but excludes non-
interventional trials. 
1.  - Clinical  trial:  Any  investigation  iq  human 
subjects intended to discover or verify the clinical, 
pharmacological  and/or  other  pharmacodynamic 
effects  of one  or  more  investigational  medicinal 
products, and/or to identify any adverse reactions to 
one  or  more  investigational  medicinal  products 
and/or to study absorption, distribution, metabolism 
and  excretion  of  one  or  more  investigational 
medicinal products with the object of ascertaining 
their safety and/or efficacy. 
This  includes clinical trials performed either on a 
single site or on multiple sites in the course of  these 
clinical trials. 
2.  - Multi-centre  clinical  trial:  A  clinical  trial 
conducted  according  to  a  single  protocol  but  at 
more than one site, and therefore, by more than one 
investigator, in which the trial sites may be located 
in a single Member State, in a q.umber of Member 
States and/or in Member States and third countries. 
3. - Non-interventional clinical trial: A clinical trial 
where the selection of subjects or the attribution of 
medicinal products or the examinations carried out 
or medical and biological follow-up of subjects fall 
within current medical practice. 
Ethics  Committee:  An  independent  body  4.  Investigational  medicinal  product:  A 
constituted of healthcare  professionals  and  non- pharmaceutical  form  of an  active  substance  or 
7 medical  members,  whose  responsibility  it  is  to 
ensure the protection of  the rights, safety and well-
being of human subjects involved in a trial and to 
provide  public  assurance  of that protection,  by, 
among other things, expressing an opinion on the 
trial protocol, the suitability of the investigator(s), 
facilities, and the methods and material to be used 
in obtaining and documenting informed consent of 
the trial subjects. 
Inspection:  The  act  by a competent authority  of 
conducting  an  official  review  of  documents, 
facilities,  records,  arrangements  for  quality 
assurance,  and  any  other  resources  that  are 
deemed by the competent authority to be related to 
the clinical trial and that may be located at ihe site 
of  the  trial,  at  the  sponsor's  and/or  contract 
research  organisation's  facilities,  or  at  other 
establishments  deemed  appropriate  by  the 
competent authority. 
Investigational  medicinal  product:  A 
pharmaceutical  form  of an  active  substance  or 
placebo being tested or used as  a- reference  in a · 
clinical trial, including a product with a marketing 
authorisation when used or assembled (formulated 
or  packaged)  in  a  way  different  from  the 
authorised form, or when used for an unauthorised 
indication,  or  when  used  to  gain  further 
iitformation about an authorised use. 
Investigator: A person responsible for the conduct 
of the  clinical  trial  at  a  trial  site.  If a  trial  is 
conducted by a team of individuals at a trial site, 
the  investigator  is  the  responsible  leader  of the 
team and may be called the principal investigator. 
Investigator's  Brochure:  A  compilation  of the 
clinical  and  non-clinical  data  on  the 
investigational  medicinal  product(s)  which  is 
·relevant  to  the  study  of  the  investigational 
medicinal product(s) in human subjects. 
Multi-centre  Trial:  A  clinical  trial  conducted 
according to a single protocol but at more than one 
site, and therefore, carried out by more than one 
investigator. 
Trial  sites  may  be  located  in  a  single  Member 
State,  in  a  number  of Member  States  and/or  in 
placebo  being  tested  or used  as  a  reference  in  a 
clil'lical  trial,  including  products  already  with  a 
marketing  authorisation  but  used  or  assembled 
(formulated or packaged)  in a  way  different from 
the  authorised  form,  or  when  used  for  an 
unauthorised  indication,  or  when  used  to  gain 
further information about the authorised form. 
5.-Sponsor: An individual, company, institution or 
organisation  which  takes  responsibility  for  the 
initiation,  management  and/or  financing  of  a 
clinical trial. 
6.  - Investigator:  A  person  responsible  for  the 
conduct of  the clinical trial at a trial site. If a trial is 
conducted by a team of  individuals at a trial site, the 
investigator  is  the  responsible  leader  of the_ team 
and may be called the principal investigator. 
7.  - Investigator's brochure:  A compilation of the 
clinical and non-clinical data on the investigational 
medicinal product or products which is relevant to 
the  study  of the  product  or products  in  human 
subjects. 
8..  - Protocol:  A  document  that  describes  the 
objective(s),  .  design,  methodology,  statistical 
considerations and organisation of a trial, the term 
"protocol"  referring  to  the  protocol,  successive 
versions of  the protocol and protocol amendments. 
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9.  - Subject:  An individual  who  takes  part  in  a 
clinical  trial,  either  as  a  -recipient  of  the 
investigational  medicinal  product  or  as  a  control 
receiving a placebo or other medicinal product. Member States and third countries. 
Non-intervenlionaltrial: A clinical trial where the 
selection of subjects or the attribution of  medicinal 
products  or  the  examinations  carried  out  or 
medical and biological follow-up of subjects falls 
within current medical practice  .. 
Protocol:  A  document  that  describes  the 
objective(s),  design,  methodology,  statistical 
considerations,  and  organisation  of a  trial.  The 
term  protocol  refers  to  protocol,  successive 
versions of  the protocol and protocol amendments. 
Serious  Adverse  Event  or  Serious  Adverse 
Reaction:  Any untoward medical occurrence that 
at  any  dose  results  in  death,  is  life-threatening, 
requires (non-elective) inpatient hospitalisation or 
prolongation of existing hospitalisation, results in 
persistent or significant disability/incapacity, or is 
a congenital anomaly/birth defect. 
Sponsor:  An  individual,  company,  institution  or 
organisation  which  takes  responsibility  for  the 
initiation,  management,  and/or  financing  of  a 
clinical trial. 
Subject:  An  individual  who  participates  in  a 
clinical  trial,  either  as  a  recipient  of  the 
· investigational medicinal product or as a control. 
Unexpected  Adverse  Reaction:  An  adverse 
reaction  not  mentioned  in  the  investigator's 
brochure  or  in  the  summary  of  product 
characteristics, if  any. 
10.  - Informed consent:  Decision to  take part in  a 
clinical trial, taken freely and given in writing after 
being  duly  informed  of the  full  details,  by  any 
responsible adult trial subject or, where appropriate, 
by  the parents, guardian or legal representative, on 
behalf of  minors and incapacitated adults. 
11.  - Ethics  committee:  An  independent  body 
c-onstituted  of healthcare  professionals  and  non-
medical  members,  whose  responsibility  it  is  to 
protect the  rights,  safety and  well-being of human 
subjects  involved  in  a trial  and  to  provide  public 
assurance of  that protection by, among other things, 
·expressing  an  opinion  on  the  trial  protocol,  the 
suitability of the  investigator(s), facilities,  and  the; 
methods and documents to inform trial subjects and 
obtain their informed consent. 
12.  - Inspection:  The act by a competent authority 
of conducting  an  official  review  of documents, 
facilities,  records,  quality  assurance  arrangements 
and  any  other  resources  that  are  deemed  by  the 
competent authority to be related to the clinical trial 
and that may be located at the site of  the trial, at the 
sponsor's  and/or  contract  research  organisation's 
facilities,  or  at  other  establishments  which  the 
competent·authority sees fit to inspect. 
13.  - Adverse  event:  Any  untoward  medical 
occurrence  in  a  patient  or  clinical  investigation 
subject administered a medicinal product and which 
does not necessarily have a causal relationship with  · 
this treatment. 
14.  - Adverse reaction: All noxious and unintended 
responses  to  an  investigational  medicinal  product 
related to any dose. 
15.  - Serious  adverse  event  or  serious  adverse 
reaction:  Any  untoward  event  or reaction  that  at 
any dose results  in  death,  threatens the life of the 
subject,  requires  non-elective  inpatient 
hospitalisation  or  prolongation  of  existing 
hospitalisation,  results  in  persistent  or  significant 
disability or incapacity or is a congenital anomaly 
or birth defect. 
16.  - Unexpected  adverse  reaction:  An  adverse 
9 1. 
2. 
CHAPTER II 
Protection of trial subjects 
Article 3 
This  Directive  is  without  prejudice  to  the 
measures  laid  down  in  Member  States 
concerning the protection of  trial subjects. 
A clinical trial may only be undertaken if the 
risks to the subject are not disproportionate to 
the  potential  benefits  of  the  medicinal 
research. The right of the subject to physical 
and  mental  integrity  shall  be  respected,  as 
well as the right to privacy. 
reaction  not  mentioned  in  the .  investigator's I 
brochure  or,  in  the  case  of  medicinal  products I 
already  authorised,  in  the  summary  of  product 
characteristics. 
Protection of clinical trial subjects 
Article 3 
1.  This  Directive  shall  apply  without prejudice to 
the national provisions on the protection of clinical 
trial subjects, if they are more comprehensive than 
the provisions of this Directive and consistent with 
the procedures and time-scales specified therein.  I 
2.  A  clinical  trial  may be  undertaken  only  if, .in 
particular: 
a) the risks to the subject are not disproportionate to 
the benefits expected for human health; 
b) the rights of the subject to  physical and mental 
integrity and to privacy are safeguarded; 
c)  the  subject  has  given  informed consent in the 
appropriate form; 
d) the subject may withdraw from the clinical trial 
at any time, without any resulting detriment to  the 
subject,  by  revoking  the  informed  consent,  as 
defined in Article 2. 
3.  The  medical  care  given  to,  and  medical  3. 
decisions made on behalf of, subjects shall be 
(Unchanged) 
4. 
the  responsibility  of  an  appropriately 
qualified  healthcare  practitioner  or,  when 
appropriate, of  a qualified dentist. 
The  trial  subject  shall  be  provided  with  a 
contact  point,  independent  of  the 
investigating team, where further information 
may be obtained. 
Ethics Committee opinion 
4.  On the responsibility of the sponsor, who shall 
adopt the consequent organisational arrangements, 
the  clinical  trial  subject  shall  be provided  with  a 
contact point, independent of the investigator team, 
from which further information may be obtained on 
the  procedure  for  the  clinical  trial,  whenever  it 
could affect the trial subject personally. 
Ethics committee o  inion 
10 I. 
2. 
Article 4 
The  function  and  responsibility  of  an 
ethics committee shall be to safeguard the 
rights,  safety  and  well-being  of all  trial 
subjects. 
Article 4 
Rcv2 diri'N.doc 
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I.  For  the  purposes  of  implementation  of  the 
clinical  trials  provided  for  by  this  Directive, .  the 
Member  States  shall  take  the  measures  necessary 
for  establishment  and  operation  of·  ethics 
committees, as defined in Article 2. 
2.  The  ethics committee shall  give  its  opinion on 
any  subject  requested  .  before  a  clinical  trial 
commences. 
In  preparing  its  opinion,  the  ethics  3.  In  preparing  its  opinion,  the  ethics  committee 
committee  shall  consider,  at  least,  the  shall consider, in particular: 
relevance of the trial  and the trial  design, 
the  protocol,  the  suitability  of  the  a)  the  relevance  of the  clinical  trial  and  the  trial 
investigator, supporting staff, and available  design; 
facilities;  the  adequacy  and  completeness 
of the  written information to  be  given to  b) the protocol; 
the subjects, their relatives, guardians and, 
if necessary,  legal  representatives and  by  c) the suitability of the investigator and supporting 
which consent is to be obtained; provision  staff; 
for compensation/ treatment in the case of 
injury or death of a subject if attributable  d) the quality of  the facilities; 
to  a  clinical  trial,  and  any  insurance  or 
. indemnity  to  cover  the  liability  of the 
investigator  and  sponsor;  the  extent  to 
which  investigators  and  subjects  may  be 
rewarded or compensated for participation 
in the trial. 
The opinion of an ethics committee shall 
be  delivered  before  a  clinical  trial 
commences. 
e)  the  adequacy  and  completeness  of the  written 
information  to  be  given  to  the  subjects,  their 
relatives,  guardians  and,  if  necessary,  legal 
representatives and by which informed consent is to 
be obtained; 
f) provision for compensation in the case of injury 
or death attributable to a clinical trial; 
g) any insurance or indemnity to cover the liability 
of  the investigator and sponsor; 
h) the arrqements for rewardina or compensatina 
investiaators and subjects for participation in the 
trial. 
(see paragraph 2) 
3.  In  order  to  apply  for. an  opinion  of an  .4.  In  order  to  obtain  the  opm10n  of an  ethics 
ethics  committee,  an  application  with  committee,  the  sponsor  shall  submit .  to  the 
documentation  shall  be  submitted.  The  committee  a  request '  for  an  opmton  with 
written  opinion  of the  ethics  committee  documentation giving the reasons for the proposed 
11 'l 
4. 
1. 
2. 
written  opmwn  of the  ethics  committee 
shall be -given to. the applicant, in writing, 
within  30  days  of  receipt  of  a  valid 
application. 
Within  that  period,  the  ethics  committee 
may send a single request for information 
supplementary to that already supplied. In 
this case the period shall be extended by a 
further 30 days. 
Article 5 
Member States shall establish a procedure 
by  which  a  single  ethics  committee 
opinion can be achieved for that Member 
State.  For  multi-centre  clinical  trials 
conducted in more than one Member State, 
this procedure shall provide for the single 
opinion for that Member State. 
Member States may,  in addition,  provide 
for an opinion of the ethics committee for 
each site on the facilities  and capabilities 
of that  site  in  relation  to  the  proposed 
clinical trial. Within 15  days of receipt of 
the opinion provided for  in paragraph  1, 
the ethics committee for the site shall, by 
issuing an opinion, either accept or reject 
the conduct of  the trial in that site. 
Article 6 
The  Commission,  in  consultation  with  the 
Member States and interested parties, shall draw 
up detailed guidance on the application format and 
I 
documentation to be submitted in an application 
1 for  an  ethical  committee  opinion,  and  on  the 
I  appropriate  safeguards  for  the  ·protection  of 
documentation giving the reasons for the proposed 
clinical trial. Within 30 days of official submission 
of  the  application  for  an  opinion  the  ethics 
committee  shall  give  its  reasoned  opinion  to  the 
sponsor and the competent authority in the Member 
State concerned. 
5.  Within  the  period  of  examination  of  the 
application  for  an  opinion,  the  ethics  committee 
niay  send  a  single  request  for  -information 
supplementary  to  that  already  supplied  by  the 
sponsor. In this case the ethics committee. shall have 
a further 30 days from receipt of the supplementary 
information  to  give  its  definitive  opmton  on the 
proposed clinical trial. 
Article 5 
1. For multi-centre clinical trials limited to a single 
Member  State,  Member  States  shall  establish  a 
procedure providing for adoption of a single ethics 
committee  opinion for  that Member  State.  In the 
case of multi-centre clinical trials  involving more 
than  one  Member  State  simultaneously,  a  single 
ethics  committee  opinion shall be given  for  each 
Member State concerned by the clinical trial. 
2.  In  the  case  of multi-centre  clinical  trials  the 
Member  States  may  provide  for  the  ethics 
committee  for  a  particular centre amongst all  the 
centres involved in the multi-centre clinical trial to 
give  an  opinion  covering  only the  facilities  and 
capabilities of that particular centre to conduct the 
1 
trial. The ethics committee for this particular centre 
shall have a maximum of 15  days from the date of 
receipt of the opinion referred to in paragraph 1 to 
give its own duly reasoned opinion: if this opinion 
·is negative, the clinical trial may not be conducted 
at  this  single  centre,  without  prejudice  to  the 
situation in the other centres concerned or to  the 
opinion referred to in paragraph 1. 
Article 6 
(Unchanged) 
12 information that is given to trial subjects. 
I. 
2. 
3. 
CHAPTER III 
Commencement of a clinical trial 
Article 7 
Before  commencing  a  clinical  trial,  an 
application  shall  be  submitted  by  the 
sponsor  to  the  Member  States  where  the 
trial will take place. 
Member States shall authorise sponsors to 
commence  clinical  trials  once  the  ethics 
committee has issued a favourable opinion. 
Member States may  however decide  that 
certain  clinical  trials  will  be  subject  to 
,  paragraph 3. 
In the case of clinical trials not covered by 
the  provisions  of paragraph  2,  Member 
States  shall  authorise  a  sponsor  to 
commence  clinical  trials  at  the  end  of a 
period of 30 days  after receipt of a  valid 
application  unless  reasoned  grounds  for 
non-acceptance  have  been notified  within 
this time period. 
Within  30  days  of receipt  of the  said 
grounds  for  non-acceptance,  the  sponsor 
may  amend  the  application  on  one 
occasion only in order to take due account 
of  the grounds set out in the notification. If 
the sponsor does not amend the application 
as provided for,  the application is deemed 
to have been rejected. 
Rcv2 uiri'N.doc 
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Commencement of a clinical trial 
Article 7 
The  Member  States  shall  take  the  measures 
necessary  to  ensure  that  the  procedure  described 
hereinafter  is  followed  for  commencement  of a 
clinical trial. 
1.  Before  commencing  any  clinical  trial,  the 
sponsor  shall  be  required  to  submit  notification 
thereof to  the competent authorities of the Member 
State or States where the sponsor plans to  conduct 
the trial at the same time as submitting the request 
for an opinion referred to in paragraph 4 of Article 
4. 
2. The sponsor may not start a clinical trial until the 
ethics  committee  has  issued .a  favourable  opinion 
and unless the competent authorities of  the Member 
State  concerned  have  notified  the  sponsor  of no 
grounds · for  non-acceptance  within  30  days  of 
receipt of  the notification referred to in paragraph 1. 
Should  this  not  be  the  case,  within  30  days  of 
receipt of the grounds for non-acceptance from the 
competent  authorities  of  the  'Member  State 
concerned,  the  sponsor  may  amend,  on  one 
occasion  only,  the· content  of  the  notification 
referred to in paragraph I of this Article in order to 
take  due  account  of the  grounds  given.  If the 
sponsor fails to amend the notification accordingly, 
the notification shall be considered rejected and the 
clinical trial may not commence. 
3.  In  the  case  of clinical  trials  on  investigational 
medicinal  products  corresponding  to  the 
13 4.  Amendments  to  the  protocol  shall  be 
notified  to  the  Member  States.  These 
amendments  shall  be  deemed  to  be 
accepted  unless  the  competent  authority 
notifies grounds for non-acceptance within 
30 days. 
medicinal  products  corresponding  to  the 
characteristics. defined  in  Part  A of the  Annex  to 
Council Regulation (EEC) No 2309/93, particularly 
produc~s intended  for  gene  therapy  and  products 
intended for cell therapy, a copy of the notification 
referred to  in  paragraph 1 of this Article or of the 
amended notification provided for in paragraph 2 of 
this  Article shall  be  sent to  the European Agency 
for the Evaluation of  Medicinal Products. 
In  the  case  of clinical  trials  on  investigational 
medicinal  products  corresponding  to  the 
characteristics  defined  in  Part  B  of the  Annex  to 
Council Regulation (EEC) No 2309/93, the sponsor 
shall  have  the  option  of sending  the  notification 
referred  to  in  paragraph  1 of this  Article  or  the 
amended notification provided for in paragraph 2 of 
this  Article  to  the  European  Agency  for  the 
Evaluation of  Medicinal Products. 
4.  However,  prior  written  authorisation  shall  be 
required  before  commencing clinical  trials  on the 
medicinal  products  referred  to  in  Part  A  of the 
Annex  to  Council  Regulation  (EEC)  No  2309/93 
and  on  all  other  medicinal  products  with  special 
characteristics defined and approved in the form of 
a directive adopted by the procedure laid down in 
Article 2c ofCouncil Directive 75/318/EEC. 
This authorisation to commence shall be granted by 
the  competent  authorities  of the  Member  States 
within 60 days of receipt of  the notification referred 
to in paragraph 1 of  this Article and after the ethics 
committee has given a favourable opinion, without 
prejudice to the procedure applicable in the event of 
the  grounds  for  non-acceptance  referred  to  in 
paragraph 2 of  this Article. 
The  abovementioned·. authorisation  to  commence 
the clinical trial shall be sent to  the· sponsor.  The 
ethics committee and the European Agency for the 
Evaluation of  Medicinal Products shall be informed 
that this authorisation has been granted. 
(see new Article 8, paragraph 1) 
14 In cases where grounds for non-acceptance 
are  raised,  the  procedure  in  paragraph  3 
shall be followed. 
5.  Notwithstanding  paragraph  4,  provisional  (see new Article 8, paragraph 2) 
urgent  safety  measures  may  be  taken  by 
the  sponsor  in  order  to  eliminate  an 
immediate hazard to trial subjects. 
6.  Within 90 days of  the end of a clinical trial  (see new Article 8, paragraph 3) 
the sponsor shall notify the Member States 
that the clinical trial is ended. This period 
shall be reduced to  15  days in the case of 
early termination of  the trial. 
7.  The  Commission  shall,  in  consultation  5.  In  consultation  with  the  Member  States,  the 
with the Member States, draw up detailed  Commission shall draw up detailed guidance on the 
guidance  on  the  format  and  contents  for  format and contents of  the notification referred to in 
applications as  well  as the  documentation  paragraph  1  of  this  Article  as  well  as  the 
to  be submitted in  relation  to  the  quality  documentation  to  be  submitted  to  support  this 
and  manufacture  of  the  investigational  notification on the quality and  manufacture of the 
medicinal  product,  any  toxicological  and  investigational medicinal product, any toxicological 
pharmacological  tests,  protocol  and  and  pharmacological  tests,  protocol  and  clinical 
clinical  information on the  investigational  information  on  the  investigational  medicinal 
medicinal  product  including  the  product  including  the  investigator's  brochure,  in 
investigator's  brochure,  in  addition  to  the  addition to the declaration of  the end of the clinical 
content of  the notification of  the end of  the  trial. 
clinical trial. 
Conduct of  a clinical trial 
Article 8 (new) 
Amendments may be made to conduct of a clinical 
trial following the procedure described hereinafter. 
1.  After  commencement  of the  clinical  trial,  the 
sponsor may  make  substantial  amendments to the 
protocol likely to have an impact on the  safety of 
the  trial  subjects  or  to  change  the  criteria  for 
scientific  evaluation,  the  criteria  for  inclusion  or 
exclusion  of trial  subjects,  the  number  of trial 
subjects, the duration of the treatment, the doses of 
the  investigational  medicinal  products  and  the 
clinical and biological examinations carried out in 
the course of follow-up of the trial subjects. In this 
case  the  sponsor  shall  notify  the  competent 
authorities of the Member State or Member States 
concerned of the reasons  for  and  content of these 
15 amendments and shall inform the ethics committee 
or committees concerned thereof and the European 
Agency for the Evaluation of Medicinal Products if 
the clinical trial in question meets the requirements 
of  the first indent of  paragraph 4 of  Article 7. 
On the basis of  the details referred to in paragraph 3 
of Article  4  and  subject  to  the  requirements  of 
Article 5, the ethics committee shall give an opinion 
on  the  proposed  amendment  within  30  days  of 
notification thereof. If  this opinion is unfavourable, 
the sponsor may not implement the amendment to 
the protocol. 
If the opinion of the ethics committee is favourable 
and the competent authorities of the Member States 
have  raised no grounds for  non-acceptance of the 
abovementioned substantial amendments within 30 
days  of  notification  thereof,  the  sponsor  shall 
proceed to  conduct the clinical  trial  following the 
amended protocol. Should this not be the case, the 
sponsor shall either take account of these grounds 
and adapt the proposed amendment to the protocol 
accordingly or withdraw the proposed amendment. 
In the  case  of clinical  trials  subject  to  the  prior 
written authorisation referred to in paragraph 4 of 
Article 7, the sponsor may not proceed to conduct 
the  clinical  trial  following  the  amended  protocol 
unless the ethics committee has given a favourable 
opinion  and  the· competent·  authorities  of  the 
Member  States  have  given  a  new  authorisation 
taking account of  these amendments. 
2.  Without prejudice to paragraph 1, in the light of 
the  circumstances,  notably  the  occurrence  of 
unexpected adverse reactions or events, the sponsor 
shall  take  appropriate  urgent  safety  measures  to 
protect the subjects  in a  clinical  trial  against any 
immediate  hazard.  The  sponsor  shall  inform  the 
competent authorities and the ethics committee of 
these measures. 
3.  Within 90 days of the end of a clinical trial the 
sponsor shall notify the competent authorities of  the 
Member State or Member States concerned and the 
ethics committee that  .l}le clinical trial has ended. If 
the trial has to be terminated early this period shall 
be  reduced  to  15  days  and  the  reasons  clearly 
explained. 
16 ..-------------------·-·  ---------------------------, 
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Exchange of information 
Article 8 
Extracts  from  the  initial  application, 
amendments  as  appropriate  and  the 
notification at the end of the clinical  trial 
shaH  be  entered by the  Member States in 
whose territory the trial takes place into a 
database accessible only to Member States, 
the European Agency for the Evaluation of 
Medicinal Products and the Commission. 
At the request of any Member State or the 
Commission,  the  competent  authority  to 
whom the trial was notified shall supply all 
appropriate  information  concerning  that 
clinical trial. 
In  the  case  of multi-centre  clinical  trials 
conducted in more than one Member State 
where  there  are  differences  between  the 
Member  States,  the  Commission  may 
request  the  Member  States  concerned  to 
establish  the  reasons  for  the  difference 
which shall be considered by all Member 
States. 
The Commission, in consultation with the 
Member  States,  shall  draw  up  detailed 
guidance  on  the  relevant  data  to  be 
included  in  this  database  as  well  as 
methods for the electronic communication 
of  the data. 
Exchange of information 
Article 9 (ex 8) 
1. The Member States in whose territory the clinical 
trial takes place shall enter in a European database, 
accessible only to  the  competent authorities of the 
Member  States,  the  European  Agency · for  the 
Evaluation  of  Medicinal  Products  and  the 
Commission, extracts from the notification referred 
to  in  paragraph  1 of Article  7,  any  amendments 
made  to  the  notification,  as  provided  for  in 
paragraph 2 of Article 7, any amendments made to 
the  protocol,  as. provided  for  in  paragraph  1  of 
Article  8,  the  favourable  opinion  of the  ethics 
committee and the declaration of  termination of the 
clinical trial. 
2.  At  the  request  of  any  Member  State,  the 
European Agency for the Evaluation of Medicinal 
Products  or  the  Commission,  the  competent 
authority  to  which  the  notification  referred  to  in 
paragraph l of Article 7 was submitted shall supply 
all  further information concerning the clinical trial 
in  question  other  than  the  data  already  in  the 
European database. 
3.  In  the  case  of  multi-centre  clinical  trials 
involving more than one Member State, where there 
are  differences  between  the  Member  States  with 
regard  to  the  conditions  for  commencement  or 
conduct of the clinical  trial,  the  Commission may 
request  the  Member States concerned  to  establish 
the  reasons  for  the  differences,  which  shall  be 
considered  by  all  the  Member  States  in 
consultations organised by the Commission with the 
assistance  of  the  European  Agency  for  the 
Evaluation of  Medicinal Products. 
4.  In  consultation  with  the  Member  States,  the 
Commission shall draw up detailed guidance on the 
relevant  data  to  be  included  in  this  European 
database which it operates with the assistance of  the 
European Agency  for  the  Evaluation of Medicinal 
Products  as  well  as  the  methods  for  electronic 
communication of the data.  This_ detailed guidance 
drawn up shall keep the data strictly confidential. 
Infringements 
17 Article 9  Article 10 (ex 9) 
I.  Where  the  conditions  of the  application- 1.  Where a Member State has objective grounds for 
cease to  be  met or in the  event that new  considering that  the  conditions  in  the  notification 
information raising doubts as to safety or  referred to in paragraph 1 of  Article 7 are no longer 
science  becomes  available,  the  Member  met or  has  information  raising  doubts  about  the 
State may suspend or prohibit the trial.  It  safety or science of  the clinical trial, it may suspend 
shall  forthwith  inform  the  other Member  or  prohibit  the  clinical  trial  and  shall  notify  the 
2. 
1. 
States and the Commission thereof.  sponsor thereof. 
The Member State shall  inform the  other  In  this  case  the  Member  State  concerned  shall 
Member States and the Commission of the  forthwith  inform  the  other  Member  States,  the 
decisions taken and the  reasons  for  those  ethics committee concerned, the European Agency 
decisions.  for  the  Evaluation of Medicinal  Products  and  the 
Where  a  Member State  is  of the  opinion 
that the sponsor or the  investigator is  no 
longer  fulfilling  his  obligations  as  laid 
down,  it shall  forthwith  inform  the  other 
Member  States  and  the  Commission, 
stating the reasons in detail and indicating 
the course of  action. 
The Member State shall forthwith inform 
the Commission of the commencement of 
any infringement proceedings. 
CHAPTER IV 
Manufacture, import and labelling of 
investigational  medicinal products 
Article 10 
Member  States  shall  take  all  appropriate 
measures  to  ensure  that  the  manufacture 
and ·import  of investigational  medicinal 
products  is  su9ject  to  the  authorisation 
referred  to  in  Article  -16  of  Council 
Directive 75/319/EEC4. 
Commission' of its decision to  suspend or prohibit 
the trial and the reasons for the decision. 
2.  Where a Member State has objective grounds for 
considering that the sponsor or, the investigator is no 
longer meeting  the  obligations laid down,  it shall 
forthwith  inform  them,  indicating  the  course  of 
action which it considers necessary to remedy this 
state of affairs.  The Member State concerned shall 
forthwith  inform  the  ethics  committee,  the  other 
Member States and the Commission of  this plan. 
3.  Where  non-observance  of  the  provisions 
governing the conduct of clinical trials prompts a 
Member  State  to  initiate  administrative  or  legal 
proceedings against the  sponsor or investigator,  it 
shall forthwith inform the other Member States, the 
Commission and,  where appropriate, the European 
Agency for the Evaluation of  Medicinal Products. 
Manufacture and import of  investigational 
medicinal products 
Article 11 (ex 1  0) 
1.  Member  States  shall  take  all  appropriate 
measures to ensure that the manufacture, whether in 
a  Member  State  or  in  a  third  country,  of 
investigational medicinal products used in a clinical 
trial conducted in the European Community meets 
the  requirements  of  Commission  Directive 
91/356/imcs  laying  down  the  principles  of good 
manufacturing practice for  medicinal  products and 
of  the related texts. 
18 .--------------------·--------------·-·----·---·---. 
2.  Chapters  IV  and  V  of  Directive  2.  The  Member  States  shall  authorise  imports  of 
75/319/EEC shall apply to  investigational  investigational  medicinal  products  from  third 
medicinal products.  countries  and  free  movement  thereof within  the 
Community, provided the qualified person referred 
to in paragraph 3 can certify that quality control and 
batch approval have been carried out in  accordance 
with paragraph 1. 
3.  A person engaging in the activities of the  3.  Any  person  engaging  in  the  activities  of the 
person  referred  to  in  Article  21  of  qualified person referred to in Article 21  of  Council 
Directive  75/319/EEC  in a  Member State  Directive  75/319/EEC  as  regards  investigational 
as  regards  investigational  medicinal  medicinal products at the time when this Directive 
products at the time when this Directive is  is  brought into  force  in  the  Member  State  where 
brought into force in that State but without  that  person  is  but  without  complying  with  the 
complying with the provisions of Article  conditions  laid  down  in  Articles  23  and  24  of 
23  and 24 of Directive 75/319/EEC shall  Council Directive 75/319/EEC shall be authorised 
be eligible to continue to engage in those  to  continue  those  activities  to  manufacture 
activities for the purpose of  manufacture of  investigational  medicinal  products· in the  Member 
investigational  medicinal  products  in  the  State concerned. 
Member State concerned. 
Article 11 
For  investigational  medicinal  products,  the 
particulars  to  appear  in,  at  least,  the  national 
language(s)  on  the  outer  packaging  of 
investigational medicinal products or, where there 
is  no  outer  packaging,  on  the  immediate 
packaging shall be published by the Commission 
in the  good manufacturing practice guideline on 
investigational  medicinal products to be adopted 
in  accordance  with  Article  19a  of  Directive 
75/319/EEC. 
1. 
CHAPTER V 
Compliance 
Article 12 
Compliance  with  the  provisions  of good 
clinical practice shall be verified on behalf 
of  the  Community  by  inspection  at 
relevant  sites,  including the  trial  site  and 
manufacturing site, at any laboratory used 
in  the  trial  and/or  at  the · sponsor's 
premises,  by  inspectors  appointed  by 
Member States. 
Labelling 
Article 12 (ex 11) 
(Unchanged) 
Compliance with good clinical practice 
Article 13 (ex 12) 
1.  To  verify  compliance  with  the  prov1s1ons  on 
good  clinical  practice,  the  Member  States  shall 
appoint  inspectors  to  inspect  the  sites  concerned 
with  any  clinical  trial  conducted,  particularly  the 
trial  site  or  sites,  the  manufacturing  site  for  the 
investigational  medicinal  product,  any  laboratory 
used  for  analyses  in  the  clinical  trial  and/or the 
sponsor's premises if the analyses are  carried out 
19 2.  Following inspection, an inspection report 
shall  be  prepared  which  shall  be  made 
available, upoh request, to the sponsor, any 
other  Member·  State  or  the  European 
Agency  for  the  Evaluation  of Medicinal 
Products. 
there. 
The  inspections  shall  be  conducted  by  a  Member 
State, which shall inform the European Agency for 
the Evaluation of Medicinal Products; they shall be 
carried  out  on  behalf of the  Community  and  the 
results shall be recognised by all the other Member 
States.  These  inspections  shall  be  coordinated  by 
the  European  Agency  for  the  Evaluation  of 
Medicinal Products. 
2.  Following inspection,  an inspection report shall 
be prepared and sent to the sponsor. A copy of this 
report shall be sent to the European Agency for the 
Evaluation of Medicinal  Products.  Upon  reasoned 
request, the investigator, the ethics committee, any 
other  Member  State  and  the  Commission  may 
consult this report. 
3.  Where  there  are  differences  between  3.  At  the  behest of the  European  Agency for  the 
Member  States  as  to  whether  the  Evaluation of Medicinal Products, the Commission 
provisions  of this  Directive  have  been  may  request  reinspection · should  verification  of 
·complied  with,  the  Commission  may  compliance  with  the  provisions  of this  Directive 
request  a  new  inspection.  The  co- reveal differences between Member States. 
ordination  of such  inspections  shall  be 
4. 
5. 
undertaken  by  the  European  Agency  for 
the Evaluation of  Medicinal Products. 
Subject  to  any  arrangements  which  may  4. 
have  been  ·concluded  between  the 
Community  and  third  countries,  the 
Commission  may,  upon  receipt  of  a 
reasoned request from  a Member State or 
(Unchanged) 
on its own initiative, require that the trial 
site, and/or the sponsor's premises and/or 
the  manufacturer  established  in  a  third 
country  submit  to  an  'inspection.  The 
inspection  shall  be  undertaken  by 
appropriately qualified inspectors from the 
Community. 
The Commission, in consultation with the 
Member States, the  European Agency  for 
the Evaluation of Medicinal Products and 
interested  parties,  shall  draw  up  detailed 
guidelines  on  the  documentation, 
archiving,  appropriate  qualification  of 
inspectors  and  inspection  procedures  for 
the demonstration of compliance with this 
Directive. 
5.  In  consultation  with  the  Member  States,  the 
European Agency for the Evaluation of Medicinal 
Products  and  interested  parties,  the  Commission 
shall  draw  up  detailed  guidelines  on  the 
documentation relating  to  the  clinical  trial,  which 
shall  constitute  the  master  file  on  the  trial, 
archiving,  qualifications  of  inspectors  and 
inspection procedures to  verify compliance by the 
clinical trial in question with this Directive and with 
20 1. 
2. 
3. 
the texts adopted to implement it 
CHAPTER VI 
Clinical safety reporting 
Article 13 
The  investigator  shall  report  all  serious  1. 
adverse events immediate] y to the sponsor 
except for those serious adverse events that 
the  protocol  or  investigator's  .  brochure 
identifies  as  not  requiring  iqlmediate 
reporting.  The  immediate  report  shall  be 
followed  by detailed,  written reports.  The 
immediate  and  follow-up  reports  shall 
identify subjects  by  unique code numbers 
assigned to the trial subjects. 
Adverse  events  and/or  laboratory  2. 
abnormalities identified in  the  protocol as 
critical  to  safety  evaluations  shall  be 
reported  to  the  ethics  committee  and  the 
sponsor  according  to  the  reporting 
requirements  and  within  the  time  periods 
specified in the protocol. 
For reported deaths,  the  investigator shall  3. 
supply  the  sponsor  and  the  ethics 
committee  with  any  additional  requested 
information. 
Notification of  adverse events 
Article 14 (ex 13) 
(Unchanged) 
(Unchanged) 
(Unchanged) 
4.  The  sponsor  shall  keep detailed  records  of all 
suspected adverse events which are reported to him 
hy  the  investigator or investigators.  These records 
shaJI  be  submitted to  the  Member States in  whose 
territory the clinical trial is being conducted. 
Notification of adverse reactions 
Article 15 (ex 13(4),(6) and (7)) 
4.  The  sponsor shall ensure that  all  relevant  1.  The  sponsor  shall  ensure  that  all  relevant 
information about  fatal  or life-threatening  information  about  unexpected  serious  adverse 
unexpected adverse reactions are recorded  reactions  which  are  fatal  or life-threatening  to  a 
and  reported  as  soon  as  possible  to  the  clinical trial subject are recorded and reported to the 
Member  State  in  whose  territory  the  Member  State  in  whose  territory  the  reaction 
reaction occurred, but in  any case no later  occurred  as  soon  as  possible,  but  no  later than  7 
than  seven  days  after  first  knowledge  hy  days  after the  sponsor first  knew of a .case  of this 
I 
the  sp~onsor that a case _qualifies.  All  other  !.Y_E_c_.__ _____________________  ___. 
21 serious adverse reactions that are not fatal 
or  life-threatening  shall  be  reported  as 
soon as possible but no later than within 15 
days.  The  sponsor  shall  also  inform  all 
investigators. 
All  other unexpected serious adverse reactions that  ,. 
are not fatal or life-threatening to a subject shall be 
reported by the sponsor as  soon as possible, within 
not  more  than  15  days,  to  the  Member  State  in 
whose  territory  the  reaction  occurred  and  to  the 
ethics committee. 
The  sponsor  shall  also  inform  all  the  other 
investigators  of the  unexpected  serious  adverse 
reactions to the medicinal product. 
5.  In  addition,  the  sponsor  shall  maintain  (see new Article 14, paragraph 4) 
detailed  records  of all  suspected  adverse 
events  which  are  reported  to  him  by  the 
investigator(s).  These  records  shall  be 
submitted to the Member States in whose 
territory  the  clinical  trial  is  being 
conducted. 
6.  At  least  every  12  months  during  the  2.  Once  a  year  throughout  the  clinical  trial,  the 
clinical trial, the sponsor shall provide the  sponsor shall provide the Member States in whose 
Member  States  in  whose  territory  the  territory the clinical trial is being conducted with a 
clinical trial is being conducted with a line  line  listing  of all  suspected  unexpected  serious 
listing  of all  suspected  serious  adverse  adverse  reactions  which  have  occurred  over  this 
reactions  which  have  occurred  in  the  period  and  a  summary  overView  of the  subjects' 
whole  study and a summary overview of  safety in the clinical trial. 
the subjects' safety in the trial. 
7.  Each  Member  State  shall  ensure  that  all  3.  Each  Member State  shall  ensure  that,  no  later 
suspected  serious  unexpected  adverse  than  15  days  fqllowing  occurrence  within  their 
reactions  to  an  investigational  medicinal  territory,  all  suspected unexpected serious adverse 
product  occurring  within  their  territory  reactions  referred  to  in  paragraph  2  are  recorded 
which  are  brought  to  their  attention  are  and  brought  to  its  knowledge  immediately  and 
recorded and  reported  immediately to  the  subsequently notified· to  the European Agency for 
European  Agency  for  the  Evaluation  of  the Evaluation of Medicinal Products, which shall 
Medicinal Products,  and  in  no  case  later  forthwith inform  the  competent authorities  of the 
than  15  days· following  the  receipt of the  other Member States. 
8. 
information. 
The European Agency  for  the  Evaluation 
of Medicinal  Products  shall  inform  the 
competent  authorities  of  the  Member 
States. 
The Commission, in consultation with the 
European  Agency  for  the  Evaluation  of 
Medicinal  Products,  Member  States,  and 
Article 16 (ex 13(8)) 
(Unchanged) 
interested  arties, shall draw u  uidance  .._ _________  ....__ _  __,_-'-----'---'.__...__~---'----------------------' 
22 on  the  collection,  verification  and 
presentation  of  adverse  event/reaction 
reports. 
CHAPTER VII 
General provisions 
Article 14 
This Directive is without prejudice to the general 
civil  and criminal liability of the sponsor or the 
investigator. 
Unless  Member  States  have  established  precise 
conditions  for  exceptional  circumstances, 
medicinal products used in clinical trials shall not 
be  sold.  Member  States  shall  inform  the 
Commission of  such conditions. 
General provisions 
Article 17 (ex 14) 
(Unchanged) 
Article 15  Article 18 (ex 15) 
Any  amendment  which  may  be  necessary  to  (Unchanged) 
update  the  provisions  of this  Directive  to  take 
account of scientific and technical progress shall 
be adopted in accordance with the provisions of 
Article 2c of  Directive 75/318/EEC. 
Article 16  Article 19 (ex 16) 
Member States shall take all appropriate measures  Member States shall take all measures necessary to 
to  comply  with  this  Directive  before  1  January  comply with this Directive before 1 ..... 2001. They 
1999.  They  shall  forthwith  inform  the  shall forthwith inform the Commission thereof. 
Commission thereof. 
When  Member  States  adopt  these  provisions,  (Unchanaed) 
these shall contain a reference to this Directive or 
'  shall  be  aecompanied  by  such  reference  at  the 
time of their official  publication.  The procedure 
for  sueh reference  shall  be  adopted  by Member 
States. 
Member  States  shall  communicate  to  the  (Unchanged) 
Commission the text of the provisions of national 
law which they adopt in the field governed by this 
Directive. 
Article 17  Article 20 (ex 17) 
This Directive is addressed to the Member States.  (Unchanged) 
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